Piper Sandler Reiterates Overweight on TransMedics Gr, Raises Price Target to $120
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst Matt O'Brien has reiterated an Overweight rating on TransMedics Group (TMDX) and increased the price target from $95 to $120.
May 01, 2024 | 1:55 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Piper Sandler has reiterated an Overweight rating on TransMedics Group and raised the price target from $95 to $120.
The reiteration of an Overweight rating combined with a significant increase in the price target by a reputable analyst like Matt O'Brien suggests a strong bullish outlook for TransMedics Group. This is likely to positively influence investor sentiment and could lead to a short-term increase in TMDX's stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100